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Abstract  
  
Prenatal stress exposure is associated with risk for psychiatric disorders later in life. This may be 
mediated in part via enhanced exposure to glucocorticoids (GCs), known to impact neurogenesis. We 
aimed to identify molecular mediators of these effects, focusing on long-lasting epigenetic changes. In a 
human hippocampal progenitor cell (HPC) line, we assessed the short- and long-term effects of GC 
exposure during neurogenesis on mRNA expression and DNA methylation (DNAm) profiles. GC exposure 
induced changes in DNAm at 27,812 CpGs and in the expression of 3,857 transcripts (FDR≤0.1 and FC 
expression ≥|1.15|). HPC expression and GC-affected DNAm profiles were enriched for changes 
observed during human fetal brain development. Differentially methylated sites (DMSs) with GC exposure 
clustered into four trajectories over HPC-differentiation, with transient as well as long-lasting DNAm 
changes. Lasting DMSs mapped to distinct functional pathways and were selectively enriched for poised 
and bivalent enhancer marks. Lasting DMSs had little correlation with lasting expression changes, but 
were associated with a significantly enhanced transcriptional response to a second acute GC-challenge. A 
significant subset of lasting DMSs was also responsive to an acute GC-challenge in peripheral blood. 
These tissue-overlapping DMSs were used to compute a poly-epigenetic score that predicted exposure to 
conditions associated with altered prenatal GCs in newborn’s cord blood DNA. Overall, our data suggest 
that early exposure to GCs can change the set-point of future transcriptional responses to stress by 
inducing lasting DNAm changes. Such altered set-points may relate to differential vulnerability to stress 
exposure later in life. 
 
Significance Statement:  Prenatal stress exposure is associated with a wide range of health problems 
later in life. This may be mediated in part via glucocorticoid (GC) exposure during fetal development 
known to impact neurogenesis and induce epigenetic changes. Using a human fetal hippocampal 
progenitor cell line to assess the effects of GCs, we observe that exposure to GCs early during 
neurogenesis results in lasting changes in methylation (DNAm). Lasting DNAm alterations are associated 
with a significantly enhanced transcriptional response to a subsequent GC exposure. Our data suggest 
that early exposure to GCs changes the set point of future transcriptional responses to stress by inducing 
lasting DNAm changes. Such altered set points may relate to differential vulnerability to stress exposure 
later in life. 
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Introduction  
 
Early life is one of the most important and sensitive periods during the development of an individual (1). 
Exposure to stress during this critical period, as early as prenatally, has been associated with a wide 
range of health problems later in life such as increased reactivity to stress, cognitive deficits, psychiatric 
and behavioral problems (1). In addition to alterations in fetal growth and neurobehavioral development 
(2), several studies have linked exposure to prenatal stress to structural and connectivity changes in the 
offspring brain (3, 4). One of the possible mechanisms mediating the negative effects of prenatal stress 
could be increased fetal exposure to glucocorticoids (GCs) (5–7). Over the course of normal gestation, 
there is a physiological rise of 2- to 4-fold in maternal GCs that is important for proper fetal growth and 
maturation. GC exposure of the fetus is tightly controlled by a number of mechanisms, including the 
metabolism of GCs in the placenta by the 11-hydroxysteroid dehydrogenase 2 (11-HSD2) (8). Maternal 
prenatal stress, depression and anxiety have been associated with biological changes that could increase 
fetal exposure to GCs above the required physiological levels. While a number of studies have reported 
increased plasma cortisol in women experiencing stress, depression or anxiety during pregnancy, this 
effect is far from consistent (9). Maternal stress has been proposed to be associated with increased GC 
exposure of the fetus via reduced placental metabolism of cortisol to inactive metabolites by 11-HSD2 
(8). In addition, prenatal stress has also been linked to changes in the offspring’s hypothalamic-pituitary-
adrenal (HPA) axis with increased and prolonged HPA-axis reactivity consistently observed in animal 
studies with similar effects, although less pronounced, described in humans (6, 9).  
 
While likely not the sole mechanism explaining the adverse outcomes following exposure to prenatal 
stress, excessive exposure to GCs above the physiological level may contribute to the observed 
neurodevelopmental consequences. Although GCs are essential for fetal brain maturation, the developing 
brain has been shown to be especially vulnerable to excessive GCs, with lasting effects on cognition and 
cortical thickness reported (9). Effects of GC on neuronal progenitor cells have been identified as potential 
mediators of these effects (5, 10). Hippocampal neurogenesis, in particular, is of importance as this brain 
region plays an essential role in regulating the negative feedback loop of the HPA-axis. In mice, a single 
dose of dexamethasone (DEX), a synthetic GC, at embryonic day 15.5 decreased hippocampal volume 
and cell proliferation in the subgranular zone of the dentate gyrus in pups and impaired long-term 
depression and hippocampal neurogenesis in adult mice (11). In macaques, prenatal DEX exposure as 
well as prenatal stress reduced hippocampal volume and neurogenesis (12, 13). This is supported by in 
vitro data, where reduced neuronal proliferation and differentiation was observed in human multipotent 
hippocampal progenitor cells (HPCs) after DEX treatment as well as high doses of cortisol (14).  
 
The molecular mechanisms of how prenatal GC exposure might induce these long-lasting changes on 
neurogenesis and brain structure are largely unknown. There is accumulating evidence, however, that 
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epigenetic mechanisms are likely to play a major role in mediating these effects (15). At the molecular 
level, GCs bind to glucocorticoid (GR) and mineralocorticoid receptors (MR), which function as 
transcription factors (TFs) and regulate gene expression in multiple tissues (16). In addition to altering 
gene transcription, GR activation can induce changes in DNA methylation (DNAm) (17, 18). Local de-
methylation at GC responsive elements (GREs) has been reported following GR stimulation, possibly 
mediated by activating base excision repair mechanisms (19). This reduction in DNAm likely changes 
accessibility of the DNA to transcriptional regulators and impacts future transcriptional responses (20).  
 
Exposure to prenatal stress or GCs has been associated with persisting changes in DNAm in neuronal 
tissues and cells. In animal models of prenatal stress, lasting changes in DNAm in the hypothalamus or 
hippocampus have been reported in specific candidate genes (21, 22). Another set of studies have 
reported the impact of chronic administration of GCs on DNAm in adult mouse hippocampus as well as in 
a rodent primary neuronal cell line, both in candidate genes (17, 23) and at a genome-wide level (18, 24). 
Here, we extend these previous studies and systematically investigate the impact of GCs on genome-wide 
DNAm and gene expression in human HPCs undergoing neuronal differentiation (14). We examine how 
GC exposure at different stages, including proliferation, differentiation and post-differentiation, affects 
DNAm, and whether these changes are persistent. A special focus is placed on developmental DNAm and 
gene expression trajectories and how these mechanisms are altered by GC exposure during different 
developmental periods as well as the interconnection of DNAm and gene expression changes across 
time. Finally, we map the observed epigenetic changes in HPCs to measures in developing human tissues 
and assess their potential as biomarkers for prenatal GC exposure. 
 
Results 
Effects of DEX treatment during neurogenesis. 
To assess the immediate and long-lasting effects of GR activation on gene expression and DNAm during 
neurogenesis, DEX treatment was applied at four different experimental time points in HPCs (Fig. 1A and 
SI Appendix, SI Methods) followed by mRNA and DNA hybridization onto Illumina arrays. Cells were first 
treated with DEX (1 M) or vehicle (ETOH) only during the proliferation phase (Pro, 3 days) or during both 
the proliferation and neuronal differentiation phases (Pro-diff, 10 days). To assess long-lasting effects of 
DEX, cells treated during proliferation and differentiation stages were cultured for an additional 20 days 
without DEX (Pro-diff + washout (WO)). To compare DEX effects pre- and post- differentiation, cells were 
also treated with DEX or vehicle post-differentiation for 10 days followed by 20 days of WO (Post+WO). 
Clustering the HPCs gene expression profiles from the vehicle treatments with hippocampal gene 
expression data from embryonic to adult post-mortem brains of the Human Brain Transcriptome atlas (25) 
we observed that these cells most resemble second trimester pregnancy hippocampal gene expression 
(SI Appendix, SI Results and Fig. S1).  
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Using immunohistochemistry, we previously reported that DEX treatment (1 M) in HPCs decreases 
proliferation and differentiation of progenitor cells (14). Here, we predicted the proportion of neuronal, glial 
and doublecortin-positive (DCX) cells across treatments using the CellCODE algorithm (26). As previously 
described (14), DEX significantly decreased neuronal and DCX-positive cell proportions during the 
proliferation and/or differentiation phases as compared to the vehicle condition. However, the decrease in 
neuron, glial and DCX+ cell proportions did not persist after washout, indicating that these immediate 
effects are reversed within 20 days of further culture (SI Appendix, SI Results, Fig. S2A and S2B).  
 
DEX-induced changes in gene expression and DNAm during neurogenesis 
We identified significant gene expression changes in 3,512 unique transcripts (FDR≤0.1 and absolute 
FC≥1.15; SI Appendix, Table S1) following DEX treatment across the four different time points. The 
majority of the changes were observed during proliferation (Pro, n=2389 transcripts or 68%) and 
differentiation (Pro-diff,  n=1409 or 40%) (Fig. 1B). Only a small number of differentially expressed probes 
(DEPs) showed long-lasting DEX effects following washout, both in pre- and post-differentiation 
treatments (Pro-diff+WO, n=348 or 6% and Post+WO, n=212 or 0.2%, respectively) indicating that for the 
majority of the transcripts, changes were not maintained after the removal of DEX. Even though a much 
smaller number of DEPs was identified following washout (Pro-diff+WO), significant overlaps were 
observed with DEPs from the earlier time points (Pro vs. Pro-diff+WO n=80 and fisher exact p-
value=7.79x10
-5
; Pro-diff vs. Pro-diff+WO, n=70 and fisher exact p-value=6.17x10
-11
), but not with the 
post-differentiation time point (SI Appendix, Fig. S3A). The same pattern was observed for analyses on 
the probe- as well as at the gene level (Fig. 1B and SI Appendix, Fig. S3B).  
 
Significant DEX-induced DNAm changes were identified in 27,812 unique CpGs (FDR≤0.1; SI Appendix, 
Table S2) across all time points. As for gene expression, the majority of differentially methylated sites 
(DMSs) were identified in cells treated in the proliferation stage (Pro, 65.5% of total DMSs) and minimal 
effects of DEX were seen when cells were treated post-differentiation (Post+WO, 1.1% of total DMSs, Fig. 
1C). In contrast to the effects on gene expression, a significantly larger proportion of CpG sites (24.4% of 
the total DMSs) showed long-lasting DNAm changes after washout (p-value<2.2x10
-16 
based on test for 
equality of proportions). This was not the case when the cells were treated after differentiation, here a 
significantly lower proportion of DMSs (1.1%) was observed (Post+WO, proportion test p-value<2.2x10
-16
). 
DMSs identified following washout (Pro-diff+WO) shared a significant overlap with DMSs identified at the 
earlier time points, especially when mapped to genes (at the gene level: Pro-diff vs. Pro-diff+WO n=874 
and fisher exact p-value<2.2x10
-16
, and Pro vs. Pro-diff+WO n=3,194 and fisher exact p-value<2.2x10
-16
; 
SI Appendix, Fig. S3C and S3D).  
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DEX-induced DMSs have distinct trajectories during neurogenesis. 
To follow up on our observation that changes in DNAm seem to be coordinated to some degree across 
developmental stages, we sought to determine whether these changes cluster in different DNAm 
trajectories across neurogenesis. We applied the Gene Activity in Patterns Sets (GAPS) algorithm (27) to 
identify the main trajectories by clustering the DNAm profiles of the top DMSs (FDR≤0.1 and absolute 
DNAm change ≥5%, n=792; SI Appendix, Table S3). We identified four trajectories across our 
experimental conditions where 566 CpG sites were found to be uniquely associated with a specific 
trajectory (Fig. 2A, left panel). Across differentiation, DNAm levels at these DEX-responsive sites either 
decrease (green trajectory, n=71 CpGs), increase (red trajectory, n=127 CpGs) or remain relatively stable 
(blue and beige trajectories, n=330 and 38 CpGs, respectively). The effects of DEX on DNAm, while 
significant for each single CpG for at least one time point, often showed differences in the direction (more 
or less methylated). In the blue and the beige trajectories, but not the two other trajectories, significant 
DEX-induced differences in average DNAm levels were observed (SI Appendix, Fig. S4). For 24% of the 
sites across all 4 trajectories, DEX-induced significant methylation changes that occur early in 
neurogenesis are maintained following the washout of DEX. At this time point (Pro-diff+WO), CpGs in the 
beige trajectory show the largest effects. We next mapped these 566 sites to their closest genes and 
performed enrichment analysis in Gene Ontology (GO) categories. Overall, genes mapped to these 
DNAm trajectories are involved in cellular and organ development, transcription, neurogenesis and 
neuronal differentiation (Fig. 2B). For the majority of the genes (72%), we observe the expected inverse 
correlation between DNAm and mRNA expression profiles during proliferation and differentiation. For 142 
of the transcripts mapped to the individual DNAm trajectories, DEX induced significant changes in mRNA 
expression during the proliferation and/or differentiation stages (see Fig. 2C for examples) but this was 
only observed for 18 transcripts following washout (Pro-diff+WO). The lack of concomitant mRNA 
expression and DNAm changes following the washout of DEX is also evident for all DMSs showing lasting 
DNAm changes (6,895 CpGs), where only 2.6% of the associated transcripts (4,368 transcripts) show 
long-lasting expression changes. The top DMS showing the largest long-lasting demethylation change (-
20.1%, cg14284211) from the beige trajectory is located in the FK506 binding protein 5 (FKBP5) locus. 
Fine mapping of additional CpGs in this locus using targeted bisulfite sequencing show similar long-lasting 
demethylation across multiple GREs of this locus (SI Appendix, SI Results, Table S4 and Fig. S5). 
 
To better understand what may drive these changes in DNAm, we tested if gene expression of enzymes 
involved in DNAm processes are affected by DEX at the different time points. qRT-PCR results show that 
TET1 and UHRF1, but not other enzymes, are significantly upregulated by DEX in the Pro-diff treatment 
stage after correcting for relative changes in neuron, glial and DCX+ cell proportions (SI Appendix, Fig. 
S6).  
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Functional annotation of DEX-induced DMSs.  
To annotate the biological functions of the DEX-induced changes observed, we performed multi-level 
ontology analysis (MONA) combining the results from DNAm and mRNA expression to identify common 
Gene Ontology biological processes between the two datasets. This analysis revealed an enrichment in 
pathways involved in neurogenesis as well as in the regulation of transcription across our time points (SI 
Appendix, SI Results and Fig. S7A). Interestingly, a set of pathways was exclusively associated with 
DNAm changes occurring in the Pro-diff+WO condition with associated gene expression changes at this 
time point as well as in the earlier time points. These were axon development, actin filament organization, 
negative regulation of cell proliferation, small GTPase mediated signal transduction, and neuropeptide 
signaling pathways. This indicates that biological functions associated with lasting DNAm changes show 
earlier differential mRNA expression after DEX during proliferation and differentiation.  
 
We next aimed to characterize the regulatory function of the genomic locations of our DEX responsive 
DMSs. Using GR ChIP-Seq peaks from ENCODE lymphoblastoid cell lines exposed to DEX, we observed 
significant enrichment within GREs for DMSs in Pro-diff and Pro-diff+WO (p-values<0.001, OR=1.59 and 
1.25, respectively) while Pro and Post+WO treatments were not enriched for GR binding sites (Fig. 3A). 
Using the 15-states ChromHMM annotation of the Roadmap Epigenomics project for hippocampal tissue 
(28), we observed that DMSs of Pro, Pro-diff and Pro-diff+WO treatments are enriched within enhancers 
and flanking active transcription start site (Fig. 3A). Interestingly, an overrepresentation of multiple 
bivalent and/or poised states characterized by the presence of both activating and repressive histone 
marks was exclusively observed for the long-lasting DMSs (Fig. 3A and SI Appendix, Fig. S7B). 
 
DNAm changes induced by prolonged GC exposure during neurogenesis are associated with enhanced 
responsivity of target transcripts to a subsequent acute GC challenge.  
The above presented analyses showed that early DEX exposure only leads to minimal lasting gene 
expression changes, but to substantial changes in DNAm within regulatory regions. Such changes in 
DNAm may poise the target transcripts to a more exaggerated transcriptional response to a subsequent 
activation of the GR. To test this hypothesis, we used a combination of treatments with the early 10 days 
exposure to 1 M DEX, followed by the 20 days of washout and a single acute challenge of DEX at a 
lower concentration (100 nM) for 4 hours and compared it to a single acute challenge of DEX in cells 
treated with vehicle during the early 10 days exposure (see schema  Fig. 3B and SI Appendix, SI 
Results). We focused this analysis on all transcripts that mapped to a CpG showing long-lasting DNAm 
changes (n=3,852 transcripts nearby 6,895 Pro-diff +WO CpGs). We identified 702  transcripts (18.2%) 
with significant changes in gene expression after the additional acute challenge of DEX in comparison to 
cells treated with vehicle (Pro-diff+WO+acute, FDR≤0.1 and FC≥|1.15|; SI Appendix, Table S5). This 
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fraction was substantially higher than the one previously observed in Pro-diff+WO without the acute 
stimulation (n=86 transcripts or 2.4%), or in cells exposed to the same acute challenge but treated with 
vehicle during proliferation and differentiation (n=254 transcripts or 7.1%; SI Appendix, Table S6). In 
addition, these transcripts exhibited an overall larger magnitude of change in gene expression following 
the second acute challenge (mean absolute FC=|1.29| ± 0.19, range from -3.25 to 2.86) as compared to 
minimal non-significant changes observed in the Pro-diff+WO treatment without acute challenge (mean 
FC=|1.06| ± 0.07, range from -1.42 to 1.72, p-value Wilcoxon test<2.2x10
-16
) or the acute challenge alone 
(mean FC=|1.22| ± 0.1, range from -1.93 to 1.74, p-value Wilcoxon test<2.2x10
-16
, Fig. 3B and SI 
Appendix Fig. S8). Together these results indicate that at least a subset of the long-lasting DMSs prime 
neighboring loci to be more responsive to subsequent GR activation.  
 
Interestingly, the lasting DMSs associated genes with an increased response to subsequent DEX 
exposure (702 transcripts mapping to 1,282 CpGs) showed stronger enrichment among previously 
reported DMSs regulated during fetal development (29) as compared to all the long-lasting DMSs (Pro-
diff+WO+acute permutation p-value=0.004 OR=1.3 compared to Pro-diff+WO permutation p-value<0.001, 
OR=1.23; SI Appendix, SI Results).  
 
Cross-tissues relevance of DEX induced differential DNAm and potential as biomarker. 
Although GR-responsive changes in DNAm are likely to be largely tissue-specific (20), overlapping DNAm 
changes have been reported in specific loci and may serve as biomarkers of exposure in peripheral 
tissues as observed in mice (23). To test this, we performed an enrichment analysis between the lasting 
DMSs in HPCs and DEX associated DNAm changes in human blood cells from the MPIP cohort (n=113). 
In this dataset, we identified 26,264 CpGs with significant changes in DNAm (FDR≤0.01 and absolute 
change in DNAm ≥2%) after correcting for confounders including cell type proportions. We observed a 
significant overlap of 496 sites between these DEX-responsive CpGs (permutation p-value<0.001 and 
OR=1.1976; Fig. 3C and SI Appendix, SI Results, Fig. S9 and Table S7). 
 
We next wanted to test whether the lasting DNAm changes in HPCs with common DEX-induced changes 
in peripheral blood could serve as biomarker for prenatal GC exposure in newborns. For this purpose, we 
used data from 817 newborns and their mothers within the Preeclampsia and Intrauterine Growth 
Restriction (PREDO) longitudinal cohort (30). We focused our analyses on pregnancy conditions related to 
higher prenatal GC levels: prenatal treatment with betamethasone, a synthetic GC, as well as the 
cumulative severity of maternal depression and anxiety symptoms throughout pregnancy. Using the 
overlapping 496 GC-responsive CpGs in blood and HPCs, we computed a weighted poly-epigenetic score 
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using an elastic-net regression which selected 24 CpG sites within 24 distinct loci. The weights were 
determined from the DEX-associated changes in peripheral blood (MPIP cohort) with the majority 
displaying reduced methylation after DEX (SI Appendix, SI Results, Fig. S9 and Table S8). Lower 
weights were associated with higher de-methylation in blood following DEX exposure (β=0.077, p=0.04; SI 
Appendix, Fig. S10). Applying this combined GC-responsive poly-epigenetic score to DNAm measured in 
cord blood, we observed a significant association of this score with maternal anxiety (β=-0.0011, 
SE=0.00054, p=0.044, Fig. 3D) and maternal depression (β=-0.0015, SE=0.00066, p=0.022, Fig. 3E), 
with a lower poly-epigenetic score observed in newborns exposed to higher depressive or anxiety 
symptoms. No significant association was seen with betamethasone treatment (β=-0.0039, SE=0.019, 
p=0.84), but here, only a small number of newborns (n=35) were exposed to pre-delivery betamethasone 
treatment. However, as expected, the direction of the associations of betamethasone exposure, maternal 
depression and anxiety with the score was the same. 
 
Discussion 
Using a human fetal HPC line, we observed that exposure to GCs during proliferation and differentiation, 
but not once the cells are differentiated, results in lasting changes in DNAm (Fig. 1C). These lasting 
DNAm changes are not correlated with strong baseline changes in gene transcription, but with an 
enhanced responsivity of the target transcripts to a second GC challenge (Fig. 3B). This suggests that 
early exposure to GCs may have a lasting impact on nervous system development not only by altering 
proliferation and neuronal differentiation rates as previously reported (5), but also by priming relevant 
transcripts to an altered transcriptional response upon subsequent GR activation. The induction of such 
poised or metaplastic states could then contribute to the increased risk for behavioral problems and 
psychiatric disorders observed with prenatal GC exposure (9). In fact, the level of DNAm of these lasting 
DMSs is regulated during human fetal brain development especially for those linked to altered gene 
expression to a subsequent GC exposure. Moreover, when we used a subset of the DMSs showing 
lasting effects in HPCs and acute effects in blood to compute a GC-responsive poly-epigenetic score in 
newborns’ cord blood DNA, this score showed significant associations with maternal depression and 
anxiety (Fig. 3D and 3E). This could suggest that the findings of our in vitro model may translate to human 
pregnancy and that DMSs with cross-tissue effects could serve as biomarkers for conditions associated 
with prenatal GC exposure. 
 
Unique functional role of lasting DNAm changes. 
The lasting DMSs identified were distinct from the other DMSs with only a limited overlap on the CpG level 
with DMSs following treatment during proliferation and differentiation (n=180 overlapping CpGs or 2.6%; 
SI Appendix, Fig. S3C). Indeed, unique GO terms relevant for the function of differentiated neurons were 
identified for genes mapped to these DMSs (SI Appendix, Fig. S7A).  This suggests that within the 
lasting DMSs, there could be at least two major categories, one related to differences in 
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neurodevelopment and the other to functional differences in mature cells. Prenatal GCs could thus not 
only impact on neuronal proliferation and differentiation as such, but also change the sensitivity of more 
mature cells or tissues to stress exposure later in life. Indeed, an altered sensitivity to postnatal stressors 
following prenatal stress exposure termed metaplasticity has been proposed as model for how prenatal 
environments may impact long-term risk trajectories (9, 31). This model suggests that different adaptive 
physiological responses to stress in individuals could be poised by prenatal stress (here we suggest via 
epigenetic mechanisms) but triggered by various postnatal environments giving rise to the observed 
variety of short- and long-term phenotypic outcomes (see SI Appendix, SI Discussion for a detailed 
description of this adaptive model).  
 
In line with this model, the lasting DMSs were also enriched for a specific subset of chromatin marks (see 
Fig. 3A) including bivalent/poised TSS, flanking bivalent and bivalent enhancers. Bivalent/poised 
chromatin states are characterized by the presence of both activating and repressive chromatin marks and 
are associated with paused RNA polymerase II (RNA PolII) that can be quickly released into productive 
transcription, a common feature of stress-responsive genes in yeast but also observed in humans (32). 
Previous work investigating chromatin accessibility induced by GR activation identified a subset for which 
heightened sensitivity was retained as a “memory” of the hormone induction following withdrawal (33). In 
line with these observations, our results of enhanced gene expression changes following a subsequent 
GCs exposure for a subset of these long-lasting DMSs would suggest that these sites allow the cell to 
adjust its transcriptional response dependent on previous exposure. Although bivalency has been 
observed in differentiated tissues, it is important to note that the Roadmap data used for the enrichment 
analysis originate from bulk hippocampal tissue and that our DNAm profiles in HPCs are also from a cell 
mixture. Therefore, we cannot differentiate whether these sites are indeed localized at bivalent/poised 
state of the same nucleosome or in different cells harboring one or the other chromatin marks. 
Nevertheless, the fact that the long-lasting DMSs are enriched among these regulatory marks and 
associate with altered expression following a subsequent exposure to GCs suggest a role for these sites 
in regulating or priming future gene expression responses to GCs, be it in a cell type specific manner or 
within the context of a mixed tissue, with distinct GC-sensitivities. These effects could thus alter the set-
point of ensembles of cells to future stress exposure. 
 
Molecular mechanisms inducing DNAm changes. 
What could be the mechanisms driving these lasting DNAm changes? GC-induced changes in DNAm  
may be direct downstream effects of GC-action at the respective enhancer elements, but may in part also 
be secondary to altered proliferation and differentiation observed following DEX treatment. In our previous 
work using a GR antagonist (14) as well as an inhibitor of SGK1 (34), an activator of GR, we have shown 
that both treatments block DEX-induced reduction in proliferation, providing evidence that at least some of 
these changes maybe more directly downstream of GR activation. From our data we observed that lasting 
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DNAm were enriched in GREs and for these sites only, we observed a larger fraction of de-methylation vs. 
hyper-methylation after DEX (SI Appendix, Fig. S7B). This is concordant with prior studies that have 
described local DNA de-methylation at GREs with GR activation (18), likely mediated by induction of base 
excision repair mechanisms (19). However, DNA de-methylation was not the rule for the lasting DNAm 
changes across all sites, with enhancers, bivalent/poised sites and TSS flanking sites showing similar 
proportions of hyper- as well as de-methylation (SI Appendix, Fig. S7B), similar to previous observations 
(18, 24). The fact that changes of DNAm were observed in both directions is also in line with our data 
showing that mRNA levels of both enzymes associated with de-methylation (TET1) as well as re-
methylation (UHRF1) were affected by DEX following treatment during proliferation and differentiation (SI 
Appendix, Fig. S6). In contrast, changes in mRNA expression of TET1 and UHRF1 as well as differences 
in cell type proportions were not observed anymore following the 20 days of washout although differences 
in DNAm are observed. These results suggest that long-lasting DNAm changes are not the result of strong 
and sustained global expression changes in epigenetic writers. However, they might result from a locus-
specific recruitment and/or activation of these enzymes in response to GCs initiated in a small number of 
cells/alleles during proliferation and differentiation and continue to spread after the removal of DEX. 
Indeed, although not significant, we observed the same direction of changes in DNAm at the earlier time 
points (Pro and/or Pro-diff) for 54% of the long-lasting DMSs.  
 
Cross-tissues GC-responsive CpGs as biomarker for prenatal exposure. 
Lastly, we wanted to understand whether lasting changes in DNAm in our in vitro model would also be 
observed in human blood. While previous studies in mice have shown that GC-induced DNAm changes 
are mostly tissue specific (18), overlapping changes have been reported and may be aggregated in those 
GR-responsive enhancers with common functionality across tissues (23). We also identified a subset of 
lasting HPC DMSs that were also acutely responsive to DEX in peripheral blood (n=496 CpGs, Fig. 3C). 
In addition to be predictive of maternal stress exposures when combined into a GC-responsive poly-
epigenetic score, these cross-tissues CpGs were also significantly enriched in DNAm changes observed 
in cord blood of newborns exposed to pre-delivery administration of the synthetic GC, betamethasone, as 
well as maternal anxiety and depression (SI Appendix, SI Results and Table S7). A number of studies 
have reported that the two latter conditions might also be accompanied by increased fetal GC exposure, 
by either increasing maternal GC, decreasing placental GC metabolism or activating the offspring’s HPA-
axis (5, 6). Although not directly tested in our newborn cohort, maternal prenatal stress may also impact 
the newborn’s DNAm profiles via other systems, such as immune activation with reciprocal interactions of 
the immune and the stress systems (35, 36).  
 
These DNAm changes in newborn may be markers for risk, as betamethasone exposure has been shown 
to be associated with mental health problems in children (44) and conditions associated with altered fetal 
GC exposure, including maternal depression and anxiety but also infections have been associated with a 
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number of neurodevelopmental abnormalities (6, 9, 35). The fact that our cross-tissues GC-responsive 
poly-epigenetic score significantly predicted both the severity of maternal prenatal depression as well as 
anxiety suggests that these sites could serve as biomarkers for prenatal GC exposure (Fig. 3D and 3E). 
Lower scores reflecting more de-methylation following GC exposure (SI Appendix, Fig. S10B) were 
associated with exposure to higher maternal depressive and anxiety symptoms over pregnancy. The 
direction of association, together with the overlapping findings from prenatal betamethasone treatment, 
would be in line with higher GC exposure in offspring of mothers with prenatal anxiety and depression. 
Given that prenatal GC levels were not measured in the PREDO cohort, we cannot directly test this 
proposition. It is also important to note that although we observed significant associations, the small effect 
sizes (β=-0.0011 for maternal anxiety and β=-0.0015 for maternal depression) are indicative that only a 
very small portion of the variance in symptoms is explained by the cross-tissues GC-responsive poly-
epigenetic score (R
2
=0.6% for maternal anxiety and 0.3% for maternal depression) and would likely have 
small, clinically not relevant predictive power. Additional work is needed to further develop the score as 
well as replicate these associations in additional longitudinal cohorts with measure of GCs as well as early 
intervention studies to assess its ability to predict change in postnatal stress exposure. 
 
Conclusions 
Overall, our data suggest that GC-induced DNAm reflects a complex pattern of changes likely related to 
effects on proliferation and differentiation as well as lasting changes in more mature tissues. These lasting 
changes may specifically target pathways important for neuronal transmission and prime target genes to 
an altered responsivity to subsequent GC exposure. By this, prenatal exposure to GCs could not only alter 
neurodevelopmental trajectories but also change the set-point of stress-reactivity of adult tissues. 
Together these two factors could influence and increase the risk for psychiatric disorders.  
 
Materials and Methods 
Materials, experimental procedures and data analysis for the culture and gene expression and methylation 
profiling of immortalized, multipotent human fetal HPC line HPC03A/07 as well as methylation profiling in 
blood samples of the Max Planck Institute of Psychiatry (MPIP, n=113) and PREDO (n=817) cohorts are 
described in SI Appendix, SI Materials and Methods. The MPIP cohort study protocol was approved by the 
local ethics committee and all individuals gave written informed consent. The PREDO study protocol was 
approved by the Ethical Committees of the Helsinki and Uusimaa Hospital District and by the participating 
hospitals. A written informed consent was obtained from all women. Data from the HPC gene expression 
microarray experiments were deposited at the GEO repository, GSE119842 and GSE119843 and HPC 
methylation data at GSE119846. 
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Figure legends 
 
Figure 1. DEX-induced changes in gene expression and DNA methylation across treatments. (A) 
Schema illustrating the different treatments with Vehicle or DEX (1 M) applied to HPCs across 
neurogenesis. (B) Number of differentially expressed probes (DEP) and (C) differentially methylated sites 
(DMS) induced by DEX across treatments. The bar on the left represent the number of significant probes 
from the array and on the right the number of genes mapped to these probes for each treatment.  
 
Figure 2. Top DEX-induced differentially methylated sites cluster into four distinct trajectories 
during neurogenesis. (A) DNAm of the vehicle (dashed line) and DEX treatments across our 
experimental conditions for DMSs belonging to each trajectory identified by GAPS algorithm. The average 
DNAm and SEM overall sites within each trajectory appear in bold. (B) Top significantly enriched clusters 
of GO biological process terms for genes mapped to DMSs within each trajectory. (C) Boxplot of the 
methylation levels of a representative CpG site for each trajectory and its associated gene expression 
levels across treatments. 
 
Figure 3. Functionality of the long-lasting differentially methylated sites induced by glucocorticoid 
receptor activation. (A) Heatmap of enrichment results for GR-Chip-seq binding sites and predicted 
ChromHMM states for each treatment (colors display fold enrichment and stars indicate significant 
permutation p-values <0.05). (B) Violin plot showing the fold change (DEX - vehicles) in gene expression 
for each treatment condition of the 3,852 closest transcripts that map to CpGs showing long-lasting DNAm 
changes (Pro-diff+WO, n=6,895 CpGs). Below a schema illustrating the previous Pro-diff+WO treatment 
and the two acute challenge treatments applied. Significant transcripts for each treatment condition are 
marked in red. (C) Overlap of DEX-responsive DMSs in HPCs (Pro-diff+WO) and human peripheral blood 
cells of the MPIP cohort. Associations between maternal (D) depression (β=-0.0015, SE=0.00066, 
p=0.022) and (E) anxiety (β=-0.0011, SE=0.00054, p=0.044) during pregnancy and the poly-epigenetic 
score computed for 817 newborns’ cord blood DNA samples.  
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